Found: 93
Select item for more details and to access through your institution.
Diagnostic performance of whole-body [<sup>18</sup>F]FDG PET/MR in cancer M staging: A systematic review and meta-analysis.
- Published in:
- European Radiology, 2024, v. 34, n. 1, p. 673, doi. 10.1007/s00330-023-10009-3
- By:
- Publication type:
- Article
Fatal Interstitial Pneumonitis Related to Rituximab-Containing Regimen.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 6, n. 5, p. 407, doi. 10.3816/clm.2006.n.019
- By:
- Publication type:
- Article
The clinical consequences of functional adrenal uptake in the absence of cross-sectional mass on FDG-PET/CT in oncology patients.
- Published in:
- Langenbeck's Archives of Surgery, 2022, v. 407, n. 4, p. 1677, doi. 10.1007/s00423-021-02379-3
- By:
- Publication type:
- Article
<sup>18</sup>F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center.
- Published in:
- Current Oncology, 2021, v. 28, n. 5, p. 3251, doi. 10.3390/curroncol28050282
- By:
- Publication type:
- Article
MRI classification and characterization of complex ovarian masses.
- Published in:
- Applied Radiology, 2017, v. 46, n. 3, p. 6, doi. 10.37549/ar2362
- By:
- Publication type:
- Article
Ultra-low dose CT abdomen and pelvis for the detection of acute abdominal pathology in the emergency room: initial experience from an academic hospital.
- Published in:
- Emergency Radiology, 2021, v. 28, n. 1, p. 15, doi. 10.1007/s10140-020-01804-2
- By:
- Publication type:
- Article
Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 5, p. 583, doi. 10.1002/ajh.26500
- By:
- Publication type:
- Article
Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis.
- Published in:
- European Journal of Hybrid Imaging, 2021, v. 5, n. 1, p. 1, doi. 10.1186/s41824-021-00119-w
- By:
- Publication type:
- Article
Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis.
- Published in:
- European Journal of Hybrid Imaging, 2021, v. 5, n. 1, p. 1, doi. 10.1186/s41824-021-00119-w
- By:
- Publication type:
- Article
The [ 18 F]F-FDG PET/CT Radiomics Classifier of Histologic Subtypes and Anatomical Disease Origins across Various Malignancies: A Proof-of-Principle Study.
- Published in:
- Cancers, 2024, v. 16, n. 10, p. 1873, doi. 10.3390/cancers16101873
- By:
- Publication type:
- Article
Impact of the COVID-19 Pandemic on Staging Oncologic PET/CT Imaging and Patient Outcome in a Public Healthcare Context: Overview and Follow Up of the First Two Years of the Pandemic.
- Published in:
- Cancers, 2023, v. 15, n. 22, p. 5358, doi. 10.3390/cancers15225358
- By:
- Publication type:
- Article
Disparity and Diversity in NSCLC Imaging and Genomics: Evaluation of a Mature, Multicenter Database.
- Published in:
- Cancers, 2023, v. 15, n. 7, p. 2096, doi. 10.3390/cancers15072096
- By:
- Publication type:
- Article
Combination of FDG PET/CT Radiomics and Clinical Parameters for Outcome Prediction in Patients with Hodgkin's Lymphoma.
- Published in:
- Cancers, 2023, v. 15, n. 7, p. 2056, doi. 10.3390/cancers15072056
- By:
- Publication type:
- Article
CT Radiomics and Whole Genome Sequencing in Patients with Pancreatic Ductal Adenocarcinoma: Predictive Radiogenomics Modeling.
- Published in:
- Cancers, 2022, v. 14, n. 24, p. 6224, doi. 10.3390/cancers14246224
- By:
- Publication type:
- Article
Prognostic Value of [18F]-FDG PET/CT Radiomics Combined with Sarcopenia Status among Patients with Advanced Gastroesophageal Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 21, p. 5314, doi. 10.3390/cancers14215314
- By:
- Publication type:
- Article
Nasopharyngeal Carcinoma Radiomic Evaluation with Serial PET/CT: Exploring Features Predictive of Survival in Patients with Long-Term Follow-Up.
- Published in:
- Cancers, 2022, v. 14, n. 13, p. N.PAG, doi. 10.3390/cancers14133105
- By:
- Publication type:
- Article
18 F-Fluoroazomycin Arabinoside (FAZA) PET/MR as a Biomarker of Hypoxia in Rectal Cancer: A Pilot Study.
- Published in:
- Tomography: A Journal for Imaging Research, 2024, v. 10, n. 9, p. 1354, doi. 10.3390/tomography10090102
- By:
- Publication type:
- Article
Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.722430
- By:
- Publication type:
- Article
Convolutional neural networks for improving image quality with noisy PET data.
- Published in:
- EJNMMI Research, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1186/s13550-020-00695-1
- By:
- Publication type:
- Article
Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin’s lymphoma.
- Published in:
- European Journal of Haematology, 2007, v. 79, n. 2, p. 150, doi. 10.1111/j.1600-0609.2007.00894.x
- By:
- Publication type:
- Article
PET-CT imaging of combined brachial and lumbosacral neurolymphomatosis.
- Published in:
- 2005
- By:
- Publication type:
- Book Review
Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial.
- Published in:
- Cancer Imaging, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s40644-023-00570-x
- By:
- Publication type:
- Article
The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2006, v. 33, n. 5, p. 541, doi. 10.1007/s00259-005-0056-4
- By:
- Publication type:
- Article
FDG-PET parameters predict for recurrence in anal cancer - results from a prospective, multicentre clinical trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Association of Free-to-Total PSA Ratio and <sup>18</sup>F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 10, p. 1, doi. 10.2967/jnumed.124.267877
- By:
- Publication type:
- Article
[ <sup>18</sup>F]FDG PET/CT in the Initial Staging and Restaging of Soft-Tissue or Bone Sarcoma in Patients with Negative or Equivocal Findings for Metastases or Limited Recurrence on Conventional Work-up: Results of a Prospective Multicenter Registry.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 9, p. 1371, doi. 10.2967/jnumed.122.265278
- By:
- Publication type:
- Article
Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>LuDOTATATE .
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.256727
- By:
- Publication type:
- Article
Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>LuDOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.256727
- By:
- Publication type:
- Article
Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>LuDOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.256727
- By:
- Publication type:
- Article
Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.256727
- By:
- Publication type:
- Article
Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.256727
- By:
- Publication type:
- Article
Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 23, doi. 10.2967/jnumed.120.256727
- By:
- Publication type:
- Article
Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.256727
- By:
- Publication type:
- Article
Quantitative <sup>68</sup>Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.256727
- By:
- Publication type:
- Article
<sup>18</sup>F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smooth Filter and Partial Volume Correction on Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.241737
- By:
- Publication type:
- Article
<sup>18</sup>F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smooth Filter and Partial Volume Correction on Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.241737
- By:
- Publication type:
- Article
<sup>18</sup>F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smooth Filter and Partial Volume Correction on Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.241737
- By:
- Publication type:
- Article
<sup>18</sup>F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smooth Filter and Partial Volume Correction on Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.120.241737
- By:
- Publication type:
- Article
<sup>18</sup>F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smooth Filter and Partial Volume Correction on Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.120.241737
- By:
- Publication type:
- Article
<sup>18</sup>F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smooth Filter and Partial Volume Correction on Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.120.241737
- By:
- Publication type:
- Article
18F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smooth Filter and Partial Volume Correction on Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.120.241737
- By:
- Publication type:
- Article
<sup>18</sup>F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smooth Filter and Partial Volume Correction on Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 4, p. 1, doi. 10.2967/jnumed.120.241737
- By:
- Publication type:
- Article
The contribution of multiparametric pelvic & whole body MR to interpretation of <sup>18</sup>F-fluoromethylcholine or <sup>68</sup>Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure following radical prostatectomy.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.118.225185
- By:
- Publication type:
- Article
The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of <sup>18</sup>F-Fluoromethylcholine or <sup>68</sup>Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 9, p. 1253, doi. 10.2967/jnumed.118.225185
- By:
- Publication type:
- Article
Prospective, Multisite, International Comparison of <sup>18</sup>F-Fluoromethylcholine PET/CT, Multiparametric MRI, and <sup>68</sup>Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 6, p. 794, doi. 10.2967/jnumed.118.220103
- By:
- Publication type:
- Article
Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on <sup>18</sup>F-Fluoroazomyin Arabinoside Uptake.
- Published in:
- Journal of Nuclear Medicine, 2016, v. 57, n. 3, p. 361, doi. 10.2967/jnumed.115.167650
- By:
- Publication type:
- Article
Publisher Correction to: <sup>18</sup>F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival.
- Published in:
- 2018
- By:
- Publication type:
- journal article
<sup>18</sup>F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Comparison of 18F-FDG-PET/CT and 18F-FDG-PET/MR imaging in oncology: a systematic review.
- Published in:
- 2017
- By:
- Publication type:
- journal article